Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab + Ipilimumab + Chemotherapy in Stage IV NSCLC
NCT03215706Phase 3Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Aug 2017
- Primary completion
- Aug 2019
- Modality
- Monoclonal Antibodies
- Countries
- 19
01
Overview
A Phase 3 trial of nivolumab, ipilimumab in non-small cell lung cancer (NSCLC), sponsored by Bristol Myers Squibb. Started Aug 2017; status: completed.
02
Drugs
nivolumabipilimumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03215706.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03215706.